Journals / Selçuk Tıp Dergisi / 2020 / Cilt: 36 - Sayı: 2

EBV Incidence in Diffuse Large B-Cell Lymphoma: A Single Center Descriptive Study

Pages
129–137
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The Revised International Prognostic Index (R-IPI) score and the overall survival time was calculated.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Since clinical and prognostic heterogeneity is observed in diffuse large B-cell lymphoma (DLBCL) patients, it is vital to determine its prognostic and predictive factors.
📊
Key Findings & Data:We aimed to reevaluate and discuss the prognostic and predictive factors of DLBCL patients who have been treated with R-CHOP in our center based on the WHO 2017 revised 4th edition.
💡
Conclusion & Impact:The Revised International Prognostic Index (R-IPI) score and the overall survival time was calculated.
🔬Design:Research Article
📍Scope:2017 Verileri
⚙️Variables:Domain Parameters

Özet

Aim: Since clinical and prognostic heterogeneity is observed in diffuse large B-cell lymphoma (DLBCL) patients, it is vital to determine its prognostic and predictive factors. The frequency of these factors varies geographically and ethnically. We aimed to reevaluate and discuss the prognostic and predictive factors of DLBCL patients who have been treated with R-CHOP in our center based on the WHO 2017 revised 4th edition. We also investigated the incidence of EBV in DLBCL-NOS.Patients and Methods: Patients with DLBCL-NOS diagnosed previously in our hospital between 2007-2017 and treated with R-CHOP were included in the study. We evaluated the expressions of CD10, CD5, CD30, BCL-2, BCL-6, MUM-1, MYC, LMP-1, EBNA-2, Ki-67, and p53, by immunohistochemistry, and EBV encoded RNA by in situ hybridization in 104 cases of DLBCL-NOS. The Revised International Prognostic Index (R-IPI) score and the overall survival time was calculated. Results: The study included 56 men (53.8%) and 48 women (46.2%). The median age was 64.5 years. In 59.6% of the patients, the disease had a nodal beginning, whereas in 40.4% of the patients it had an extranodal presentation. High stage (III-IV) was present in 26.5% of the GCB subtype and 43.6% of non-GCB subtype (p=0.049). A high R-IPI score was observed in 40% of GCB subtype and 54.5% of non-GCB subtype (p=0.028). Survival was significantly lower in the non-GCB subtype (log-rank test p=0.003). The EBV frequency was about 3% as it is reported in Western populations. The frequency of DEL status was 8.7%, indicating that it was associated with inferior survival (p=0.045). De novo CD5+ DLBCL ratio as 13% and it was also associated with inferior survival (p=0.013). We also found CD30+ DLBCL ratio as 11.5%, but we could not establish a significant relationship with prognosis.Conclusion: DLBCL-NOS requires detailed subtyping and elaboration of prognostic factors. ‎The frequency of DEL status and De novo CD5+ DLBCL indicated that it was associated with inferior survival. However, we could not establish a meaningful relationship of CD30+ DLBCL with prognosis.‎ Three EBV positive cases were identified and two of them were classified as ‘EBV positive large B cell lymphoma’ according to the WHO 2017 revised 4th edition.

🔖

Cite This Article

BAHAR, A. Y., KAZANCİ, U. (2020). EBV Incidence in Diffuse Large B-Cell Lymphoma: A Single Center Descriptive Study. Selçuk Tıp Dergisi, Cilt: 36 - Sayı: 2, 129–137. https://ajindex.com/articles/319245

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoetic and lymphoid tissues (Revised 4th edition). IARC Press, 2017;291-297,304-6 2. Sehn LH, Berry B, Chhanabhai M, et al. The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109(5):1857-61. 3. Scott DW, Mottok A, Ennishi D, et al. Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies. J Clin Oncol 2015;10;33(26):2848. 4. Dunleavy K, Pittaluga S, Czuczman MS, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 2009;113(24):6069-76. 5. Mathews GL, Guha R, Shinn P, et al. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proceedings of the National Academy of Sciences of the United States of America 2014;111(6):2349. 6. Nowakowski GS, LaPlant B, Macon WR, et al. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non–germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: A phase II study. J Clin Oncol 2014;33(3):251-7. 7. Offner F, Samoilova O, Osmanov E, et al. Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL. Blood 2015;126(16):1893-901. 8. Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nature medicine 2015;21(8):922. 9. Read JA, Koff JL, Nastoupil LJ, et al. Evaluating cell-of-origin subtype methods for predicting diffuse large B-cell lymphoma survival: A meta-analysis of gene expression profiling and immunohistochemistry algorithms. Clinical Lymphoma, Myeloma and Leukemia 2014;14(6):460-7. 10. Xu-Monette ZY, Tu M, Jabbar KJ, et al. Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries. Oncotarget 2015;6(8):5615. 11. Molina, TJ, Canioni, D, Copie-Bergman, C, et al. Young patients with non–germinal center B-cell–like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'